Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
Abdalla Awidi(University of Jordan), Amer M. Zeidan(Yale Cancer Center), Hisham Bawa'neh(Ministry of Health), Nada Odeh(University of Jordan), Tariq N. Aladily(University of Jordan), Ahmad Magableh(University of Jordan), Muntaser Al Zyoud(University of Jordan), Alaa Al-Shorman(University of Jordan), Yazan Hamadneh(University of Jordan), Jawad Alrawabdeh(University of Jordan), Feras Al-Fararjeh(University of Jordan), Marah Alzubi(University of Jordan)
Cited by 3
Related Papers
siRNA: Mechanism of action, challenges, and therapeutic approaches
|European Journal of Pharmacology|2021|428
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297
Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
|Journal of Orthopaedic Surgery and Research|2017|141
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
|Journal of Hematology & Oncology|2015|139